The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants
暂无分享,去创建一个
A. Destée | D. Serie | M. Farrer | D. Maraganore | M. Loriot | R. Uitti | P. Silburn | M. Heckman | K. Lohmann | G. Opala | N. Hattori | L. White | Z. Wszolek | D. Vassilatis | E. Valente | Y. Sohn | K. Wirdefeldt | A. Quattrone | A. Elbaz | S. Park | T. Lynch | E. Dardiotis | G. Hadjigeorgiou | G. Xiromerisiou | L. Stefanis | Rejko Kruger | C. Klein | B. Fiske | R. Wu | M. Bozi | Y. Kim | J. Aasly | C. Ferrarese | O. Ross | G. Auburger | S. Gispert | A. Ferraris | G. Mellick | C. Vilariño-Güell | A. Soto-Ortolaza | M. Chartier-Harlin | H. Tomiyama | L. Brighina | E. Mutez | Chin-Hsien Lin | J. Ioannidis | G. Annesi | M. Boczarska-Jedynak | B. Jeon | B. Jasińska-Myga | S. Petrucci | V. Tadić | Elli Kyratzi | J. Bacon | M. Sharma | Justin A. Bacon | B. Jasińska‐Myga
[1] D. Maraganore,et al. Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortium , 2013, Movement disorders : official journal of the Movement Disorder Society.
[2] E. Katunina,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[3] C. Tanner,et al. Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. , 2012, Parkinsonism & related disorders.
[4] I. Guella,et al. SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population , 2012, Parkinsonism & related disorders.
[5] Chuong B. Do,et al. Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.
[6] Sebastian M. Armasu,et al. Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility? , 2011, Parkinsonism & related disorders.
[7] J. Ioannidis,et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study , 2011, The Lancet Neurology.
[8] M. Farrer,et al. SNCA, MAPT, and GSK3B in Parkinson disease: a gene–gene interaction study , 2011, European journal of neurology.
[9] J. Hardy,et al. Milestones in PD genetics , 2011, Movement disorders : official journal of the Movement Disorder Society.
[10] J. Zeng,et al. LRRK2 R1398H polymorphism is associated with decreased risk of Parkinson's disease in a Han Chinese population. , 2011, Parkinsonism & related disorders.
[11] A. Destée,et al. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease , 2011, Annals of neurology.
[12] Mohamad Saad,et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.
[13] J. Jankovic,et al. Multiple LRRK2 variants modulate risk of Parkinson disease: a chinese multicenter study , 2010, Human mutation.
[14] M. Farrer,et al. Association of the MAPT locus with Parkinson’s disease , 2010, European journal of neurology.
[15] Yusuke Nakamura,et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.
[16] R. Postuma,et al. Predicting Parkinson's disease - why, when, and how? , 2009, Parkinsonism & related disorders.
[17] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[18] K. Doheny,et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.
[19] H. Shill,et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease , 2008, Neurology.
[20] M. Farrer,et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease , 2008, Annals of neurology.
[21] Colin C. McCulloch,et al. Exploring gene-environment interactions in Parkinson’s disease , 2008, Human Genetics.
[22] M. Farrer,et al. α-Synuclein and Parkinson disease susceptibility , 2007, Neurology.
[23] M. Farrer,et al. Familial genes in sporadic disease: Common variants of α-synuclein gene associate with Parkinson's disease , 2007, Mechanisms of Ageing and Development.
[24] M. Farrer,et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.
[25] M. Farrer,et al. alpha-Synuclein and Parkinson disease susceptibility. , 2007, Neurology.
[26] M. Ban,et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. , 2007, Annals of neurology.
[27] Aldo Quattrone,et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.
[28] B. Oostra,et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan , 2006, Neurogenetics.
[29] H. Inoko,et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. , 2006, Human molecular genetics.
[30] M. Farrer,et al. Interaction of α‐synuclein and tau genotypes in Parkinson's disease , 2005 .
[31] M. Farrer,et al. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. , 2005, Annals of neurology.
[32] A. Singleton,et al. The tau H2 haplotype is almost exclusively Caucasian in origin , 2004, Neuroscience Letters.
[33] M. Farrer,et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. , 2004, American journal of human genetics.
[34] A J Lees,et al. Tau gene and Parkinson’s disease: a case–control study and meta-analysis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[35] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[36] R. Krüger,et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype , 1999, Annals of neurology.
[37] D. Maraganore,et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.
[38] S. Gilman,et al. Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.
[39] H. Payami,et al. Genetic Epidemiology of Parkinson's Disease , 1998, Journal of geriatric psychiatry and neurology.
[40] S. Goodman,et al. The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results , 1994, Annals of Internal Medicine.
[41] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[42] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[43] C R Weinberg,et al. Applicability of the simple independent action model to epidemiologic studies involving two factors and a dichotomous outcome. , 1986, American journal of epidemiology.